d00dcdf0-3e98-41c5-9978-7a0ffceefa6c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- APICAL_SURFACE+0.300
- COAGULATION+0.300
- COMPLEMENT+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- MTORC1_SIGNALING+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.300
- ANGIOGENESIS-0.200
- HEDGEHOG_SIGNALING-0.200
- MYC_TARGETS_V1-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- ANDROGEN_RESPONSE-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- MITOTIC_SPINDLE-0.100
- PROTEIN_SECRETION-0.100
- UV_RESPONSE_DN-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BA-4077-01B-01R-1436-07 | — | — | 0.813 |
| 2 | 608d8ca8-8eeb-40a1-a95b-57eefcabbdab | — | — | 0.806 |
| 3 | s0094235 | — | — | 0.805 |
| 4 | MDT-AP-1196 | Med | Medulloblastoma | 0.800 |
| 5 | TCGA-E9-A1ND-01A-11R-A144-07 | — | E | 0.793 |
| 6 | ERR2208914 | — | — | 0.784 |
| 7 | BS_49FQXT2E | high-grade glioma | — | 0.781 |
| 8 | GSM6454748 | — | C | 0.780 |
| 9 | SRR8943003 | — | — | 0.777 |
| 10 | TCGA-4Z-AA7W-01A-11R-A39I-07 | — | — | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |